Skip to main navigation

Skip to Content

About Us
- Leadership
- Board of Directors
Our Approach
- Our Approach
- Scientific Publications
Pipeline
Investors & Media
Partnerships
Careers

Press Releases

Year

06.2.23

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

05.25.23

Terns Pharmaceuticals Announces Publication of TERN-701 Trial-in-Progress Abstract for the 2023 ASCO Annual Meeting

05.24.23

Terns Pharmaceuticals to Present at Upcoming Investor Conferences

05.22.23

Terns Pharmaceuticals to Highlight New Preclinical Data for TERN-601 Program in Obesity at the American Diabetes Association’s 83rd Annual Scientific Sessions

05.15.23

Terns Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Updates

05.9.23

Terns Pharmaceuticals to Participate in the JMP Securities 2023 Life Sciences Conference

05.3.23

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

03.27.23

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates

03.27.23

Terns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology

03.2.23

Terns Pharmaceuticals Provides Program Updates and Announces Participation at Upcoming March Investor Conferences

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Next page
Last page

TERNS
1065 East Hillsdale Blvd., Suite 100
Foster City, CA 94404 (MAP)
info@ternspharma.com
investors@ternspharma.com
media@ternspharma.com
Phone: +1 650-525-5535 Ext.101
Fax: +1 650-275-4254

About Us
Our Approach
Pipeline
Investors & Media
Partnerships
Careers
Contact Us

© 2023 Terns Pharmaceuticals, Inc. Privacy Policy